Merck & Co.'s third-quarter profit plunged 35 percent because of competition from generic drugs, lower sales of its top-selling medicine, and restructuring and acquisition charges.
It still beat Wall Street's profit expectations, but sharply lowered its own forecast for the full year, sending shares down.
Generic competition continues to hammer asthma and allergy pill Singulair, cutting sales 53 percent to $280 million. The drug brought in $5.5 billion a year until its patent expired in August 2012 and cheap copycat versions flooded the market.
The world's third-biggest drugmaker by revenue previously has weathered generic competition to its blockbusters well, usually managing to keep total sales about the same level as before big patent expirations.
"This year, we were not able to do that," CEO Kenneth Frazier said Monday in an interview with The Associated Press.
Revenue in the quarter totaled $11.03 billion, down 4 percent and below analysts' expectations for $11.13 billion.
Original headline: Merck 3Q net income falls on charges, lower sales
Most Popular Stories
- SoCalGas Reaches Record Spend on Diversity Suppliers
- Republican Jolly Wins Fla. Special Election
- Senate Dems Pull All-Nighter on Global Warming
- World Wide Web Turns 25
- Obama Seeks Overtime Pay for Salaried Workers
- Copper Plunges on China Jitters
- Vestas Ramps Up Hiring to Build Wind Turbines
- Justin Bieber Comes Between Taylor Swift and Selena Gomez
- U.S. Stocks Sink for 3rd Day in a Row
- Menendez Introduces Tough Sanctions Against Russia